Salmonella Typhi gut invasion drives hypoxic immune subsets associated with disease outcomes.
Bossel Ben-Moshe N. et al, (2025), Nat Commun, 16
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Venkatraman N. et al, (2025), Lancet Microbe, 6
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E.
Ali MS. et al, (2025), NPJ Vaccines, 10
Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.
Stockdale LK. et al, (2025), NPJ Vaccines, 10
R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial.
Kibwana E. et al, (2025), Front Immunol, 16
Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.
Bundi C. et al, (2025), Front Immunol, 16
The Future of Vaccines for Tuberculosis.
Stockdale L. and Fletcher H., (2019), Clin Chest Med, 40, 849 - 856